SPC
DMRA

Sigma Planning Corp’s Damora Therapeutics DMRA Stock Holding History

Sigma Planning Corp’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,500
Closed -$334K – 1359
2025
Q4 		$334K Buy
+14,500
New +$252K 0.01% 972

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Sigma Planning Corp's DMRA Position: Q1 2026 in Review

Sigma Planning Corp sold out of Damora Therapeutics (DMRA) in Q1 2026, closing a stake of 14,500 shares — an estimated $334K sold.

Sigma Planning Corp first reported a position in DMRA in Q4 2025 and held it in 1 quarter. The position peaked at $334K in Q4 2025. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • Sigma Planning Corp reported no remaining Damora Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sigma Planning Corp sold 14,500 Damora Therapeutics shares in Q1 2026, an estimated $334K.
  • Sigma Planning Corp first reported a position in Damora Therapeutics in Q4 2025 and held it in 1 quarter.
  • Sigma Planning Corp's Damora Therapeutics position peaked at $334K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics as of Q1 2026.

Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.